0O1O Stock Overview
A veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0O1O from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Vetoquinol SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €70.70 |
| 52 Week High | €106.20 |
| 52 Week Low | €64.50 |
| Beta | 0.95 |
| 1 Month Change | -6.97% |
| 3 Month Change | -11.40% |
| 1 Year Change | -30.96% |
| 3 Year Change | -43.53% |
| 5 Year Change | 10.12% |
| Change since IPO | 171.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0O1O | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 7.8% | 2.5% | 1.0% |
| 1Y | -31.0% | 3.1% | 10.4% |
Return vs Industry: 0O1O underperformed the UK Pharmaceuticals industry which returned 3.1% over the past year.
Return vs Market: 0O1O underperformed the UK Market which returned 10.4% over the past year.
Price Volatility
| 0O1O volatility | |
|---|---|
| 0O1O Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0O1O has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0O1O's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 2,519 | Matthieu Frechin | www.vetoquinol.com |
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France.
Vetoquinol SA Fundamentals Summary
| 0O1O fundamental statistics | |
|---|---|
| Market cap | €840.11m |
| Earnings (TTM) | €47.14m |
| Revenue (TTM) | €537.47m |
17.8x
P/E Ratio1.6x
P/S RatioIs 0O1O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0O1O income statement (TTM) | |
|---|---|
| Revenue | €537.47m |
| Cost of Revenue | €250.03m |
| Gross Profit | €287.44m |
| Other Expenses | €240.30m |
| Earnings | €47.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | 3.98 |
| Gross Margin | 53.48% |
| Net Profit Margin | 8.77% |
| Debt/Equity Ratio | 1.2% |
How did 0O1O perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield21%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 02:41 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vetoquinol SA is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carole Rozen | CA Cheuvreux |
| Arnaud Cadart | CIC Market Solutions (ESN) |
| Alexandre Letz | Gilbert Dupont |